Infanrix-IPV (diphtheria, tetanus toxoids, acellular pertussis and poliomyelitis vaccine) / GSK - LARVOL DELTA

Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial. (PubMed, PLoS Med) - "In stage one, infants were assigned (1:1) to either a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB, Pentabio PT Bio Farma, Indonesia) or a hexavalent aP vaccine (DTaP-Hib-HepB-IPV, Infanrix hexa, GlaxoSmithKline, Australia) at approximately 6 weeks old. Subsequently, all infants received the hexavalent aP vaccine at 4 and 6 months old as well as an aP vaccine at 18 months old (DTaP-IPV, Infanrix-IPV, GlaxoSmithKline, Australia)...https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371998&isReview=true. Just one registry (as above)."

Head-to-Head • Journal • Allergy • Food Hypersensitivity • Immunology • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

"CDSCO panel directs GSK to generate safety, immunogenicity data on Indian population for INFANRIX-IPV @GSK,@CDSCO_INDIA_INF #INFANRIX-IPV #gsk #cdsco https://t.co/7NwzHuWXew" (@medicaldialogs)

Clinical